Pipeline

Our precisely delivered investigational therapies – with their systemic immunotherapeutic effects and favorable tolerability profiles observed to date – have the potential to significantly improve survival while maintaining quality of life throughout all stages of disease.

CAN-2409 Mechanism of Action

CAN-3110 Mechanism of Action

We are evaluating our viral immunotherapies in a variety of solid tumors, including prostate, lung, brain and pancreatic cancer. For more information on our clinical studies, click here. Please visit our Platforms page to learn more about our viral immunotherapy approach.

PROGRAM

INDICATION

PRECLINICAL

PHASE I

PHASE II

PHASE III

Adenovirus Platform

CAN-2409
Prostate Cancer

Localized, Intermediate/High Risk, under SPA

Active Surveillance

Localized, Intermediate/High Risk, under SPA

Phase III

Intermediate/High Risk, under SPA - Phase 3

Active Surveillance

Phase II

Active Surveillance Patients - Phase 2

CAN-2409
Lung Cancer

NSCLC + PD-1/PD-L1

Phase II

NSCLC + PD-1/PD-L1 - Phase 2

CAN-2409
Pancreatic Cancer*

Advanced Non-Metastatic Pancreatic Adenocarcinoma

Phase II

Advanced Non-Metastatic Pancreatic Adenocarcinoma - Phase 2

HSV Platform

CAN-3110
Brain Cancer

Recurrent High-Grade Glioma

Phase I

Recurrent GBM - Phase 1

enLIGHTEN™ Discovery Platform

Solid Tumors

Undisclosed

Phase I

Undisclosed - Preclinical

SPA – special protocol assessment

*Enrollment paused, subject to additional funding